Strong presales, weak profit — the H2 presales case hinges on regulatory risk
Q2 delivered presales +109%, but reported PAT of ₹83.7 Cr is inflated by a ₹149 Cr Zentech exit gain. Core profit is soft. H1 presale progress is on track (37.51% of FY27 target), but H2 launches are stalled pending regulatory approvals across Bangalore, Cochin, and Mumbai — the real test is next quarter.
₹2,762 Cr
+109% YoY
₹4,200 Cr
37.51% of ₹11.2K Cr
₹83.7 Cr
+294.8% YoY (includes ₹149 Cr exceptional)
27%
within 25–30% band
₹470 Cr
Q2 alone; FY27 target ₹750 Cr
₹2,500 Cr
+31% YoY
Puravankara delivered a strong operational quarter on presales and collections, and is tracking its full-year guidance on both. But the profit story is weaker than it appears, and the next quarter carries significant regulatory risk.
Where the profit came from
Reported PAT jumped to ₹83.7 Cr, a 294.8% swing from a ₹11 Cr loss in Q2 prior year. On the surface, this looks like a blowout — but the quarter included a ₹149 Cr exceptional gain from the Zentech exit. That means the underlying operational profit is substantially softer. Without the Zentech proceeds, the company would show a significant loss. EBITDA margin of 27% is credible and within the 25–30% guidance band, but the profit-after-tax picture is heavily distorted by the one-timer.
The presale story — on track, but H2 at risk
The real earnings story is presales, not profit. Q2 presales hit ₹2,762 Cr, up 109% YoY. Combined with Q1, H1 presales are ₹4,200 Cr — exactly 37.51% of the FY27 ₹11.2K Cr target. Management maintained guidance, which implicitly requires ₹7,000+ Cr of presales in H2. The company guided to ₹15–16K Cr of launches for H2 to cover this. Collections are strong: ₹2,500 Cr in H1, up 31% YoY, and the presale-to-collection gap is narrowing. All of this tracks.
But here's the catch: multiple H2 launches are stalled at the regulatory approval stage. Bangalore's Winworth-3 project was awaiting RERA approval (flagged as 1–2 weeks away on the call, but timelines are uncertain). Cochin approval was imminent. Cuffe Parade in Mumbai may slip to Q1 FY28. Goregaon redevelopment requires 8–10 months for approval closure. If these slip further, the H2 presale target becomes unachievable, and with it, the FY27 guidance is at risk.
FY27 presales ₹11.2K Cr target maintained
SupportedH1 ₹4,200 Cr = 37.51% achieved; on track. But H2 (₹15–16K Cr launches) is contingent on regulatory approvals, some of which are pending.
EBITDA margin 25–30% band held; Q2 at 27%
SupportedReported EBITDA ₹289 Cr / ₹1,033 Cr revenue = 27.9%. Weighted avg project EBITDA 30% credible. Margin is stable, not expanding.
Debt reduction ₹470 Cr in Q2; FY27 target ₹750 Cr on track
SupportedNet debt reduced ₹470 Cr Q2 alone; ahead of proportional pace. Net leverage at 1.26x still elevated; improving but not fast.
Strong collection momentum, ₹1.3K Cr Q2 up 24% YoY
SupportedH1 collections ₹2,500 Cr up 31%; presale-to-collection gap narrowing. Execution is solid.
H2 presale pipeline ₹15–16K Cr launches planned
OverstatedPipeline cited (12+ South projects, West launches), but several are in regulatory approval pending. Cuffe Parade explicitly may slip to Q1 FY28. Achievable if approvals clear in Nov–Dec, but not assured.
What changed on this call
Presale momentum accelerating (+109% YoY)
Debt trajectory ahead of ₹750 Cr FY27 target
EBITDA margin holding at 27%, not expanding
H2 launch execution deferred; regulatory approvals pending
Zentech exit masks underlying operational profit weakness
The bull-bear ledger
Presales +109% YoY; momentum real and documented
H1 presales 37.51% of FY27 target; on track to deliver
Collections +31% H1; presale-to-collection gap narrowing
EBITDA margin 27% within guidance band; project-level 30% credible
Debt reduction ₹470 Cr ahead of pace; leverage improving
Land platform expanded (H1 ₹14.1K Cr GDV acquisitions); future upside
—
Reported PAT ₹83.7 Cr includes ₹149 Cr Zentech exceptional; core profit weak
H2 launches (₹15–16K Cr presale target) contingent on regulatory approvals, some pending
Net debt still 1.26x equity; refinancing risk if presales disappoint
New market execution risk (NCR, Goregaon redevelopment); 8–10 month approval cycles
Commercial asset leasing (Aerocity, Hebbal) may have timing risk; assumes 6–8 month to 100% occupancy
Stock down 64.74% from ATH, below all key moving averages; street skeptical
Risks, ranked by how much they should concern a holder
H2 launch regulatory approvals pending
HighBangalore Winworth-3, Cochin, Kannkapura RERA all in approval stage. Cuffe Parade explicitly at Q1 FY28 risk. If approvals slip beyond Nov–Dec, the H2 ₹15–16K Cr presale target becomes unachievable, and with it, the FY27 ₹11.2K Cr annual guidance is at risk. This is the single biggest near-term risk.
Earnings quality / exceptional-driven profit
HighReported PAT of ₹83.7 Cr is inflated by ₹149 Cr Zentech exceptional gain. Underlying operational profit is negative. This masks the true profitability of core operations. Future quarters without such exits will show much weaker profits and may reveal a loss-making core business.
Debt leverage at 1.26x equity
MediumDespite ₹470 Cr reduction Q2, net debt of ₹3.76K Cr is still 1.26x equity. The ₹14.1K Cr land acquisitions in H1 require ongoing capex and construction financing. If presales slow or collections disappoint, leverage refinancing risk could rise sharply.
New market execution (NCR, Goregaon)
MediumNCR entry (DMIC Noida) needs 4–6 month approvals (launch Q4 FY27 or Q1 FY28). Goregaon redevelopment needs 8–10 months approval closure. Both are high-opportunity but untested for Puravankara. Execution delays could defer upside and tie up capital.
Commercial asset monetization timing
MediumAerocity leasing target is 6–8 months to 100%; Hebbal capex is ₹450+ Cr over 4 years. If leasing timelines slip, the ₹330 Cr annual rental guidance and debt reduction plans will face pressure.
Residential demand sensitivity to job markets
LowSouth portfolio (Bangalore, Chennai) dependent on IT job growth. Mumbai on affordability. A 5–10% demand softness from macro slowdown is possible but not likely in near term given presale momentum and collections. Long-term risk, not imminent.
How the street is positioned
The stock price of ₹200.84 is down 64.74% from its all-time high of ₹569.6, and is trading below its 20-day, 50-day, and 200-day moving averages — a bearish setup. The RSI of 49.3 is neutral (not oversold). Volume is increasing, suggesting some institutional interest in the weakness.
FII ownership is 16.62% (slightly down from 16.73% prior quarter) and DII is negligible at 0.58%. Promoters hold 75%, a stable anchor. The modest FII trimming — even as the company beats operational targets — suggests institutions are waiting for clarity on H2 execution and the path to normalized (non-exceptional) profitability. The 64.74% drawdown from ATH is significant, but the stock is not yet in oversold territory on technicals, and the street's skepticism on H2 execution risk is understandable.
1 · Nov–Dec 2026 regulatory approvals
Bangalore Winworth-3 RERA, Cochin approval, Kannkapura RERA, and any news on Cuffe Parade will be the near-term catalyst. If these clear in the coming weeks, H2 presale momentum can ramp. If they slip further, the FY27 guidance will be at risk and the stock could re-test lows.
2 · Q3 FY27 presale print
The real test: how much H2 presale momentum actually hits the books. If H2 presales come in >₹6.5K Cr (to hit the FY27 ₹11.2K Cr target), the street will gain confidence. If materially lower, guidance will be under pressure.
3 · Recurring profit guidance / Q3 core earnings
Management should articulate what core/recurring profitability looks like without one-timers. If they can show a path to normalized net margins without asset exits, the earnings quality debate gets resolved. Until then, focus on EBITDA (27%) and presales (+109%) as the real drivers.
Puravankara is executing well on presales and debt — the operational story is sound. But the street's caution is justified: reported profit is inflated by a Zentech windfall, and the FY27 guidance hinges on H2 launches that are contingent on regulatory approvals still pending. The stock's 64% drawdown from ATH is steep, but not yet a compelling turnaround until H2 execution risk is de-risked and core profitability improves.
The number to track from here is not next-quarter profit (it will fluctuate with one-timers), but H2 presales. If the company logs >₹6.5K Cr of presales between now and March 2027, and core EBITDA margins hold at 27%, then the operational story holds and the stock has upside. If H2 presales come in materially short, guidance will miss, and refinancing risk will tighten. The verdict will be written in the presales numbers, not the reported profit.
Informational and educational content only. Not investment advice.